Duration of effect of oral long-acting stimulant medications for ADHD throughout the day
Abstract
Objective To examine duration of efficacy in long-acting stimulant treatment of attention-deficit/hyperactivity disorder (ADHD) in clinical trials using analog classroom protocols. Research design and methods Published reports of clinical trials examining duration of medication efficacy using analog classroom protocols were identified in a systematic literature search of PubMed, BIOSYS, and EMBASE, through June 2009 using combinations of terms: attention-deficit/hyperactivity disorder, ADHD, attention-deficit disorder with hyperactivity, stimulant, methylphenidate (MPH), amphetamine, laboratory school or classroom, analog classroom, math test, and Permanent Product Measure of Performance (PERMP). Reports of short-acting, nonoral or nonstimulant formulations, or inadequate data on duration of efficacy were excluded. Main outcome measures Main outcomes examined were PERMP scores for number of math problems attempted (PERMP-A) and correctly answered (PERMP-C) based on a standard 10-minute math test given at regular intervals during the postdose period. Results Fifteen trials were included in the analysis. All except one trial in adults (18-55 years) were conducted in children with ADHD (6-15 years) and employed randomized, double- or single-blind, placebo-controlled designs. Duration of efficacy, based on PERMP-A/-C scores (vs. placebo), ranged from 8 hours with long-acting MPH to 14 hours with lisdexamfetamine dimesylate; most formulations exerted therapeutic effects for 12 hou…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Long-acting preparations may minimize the daily peaks and troughs of therapeutic effects associated with shorter acting agents and may minimize the potential for rebound symptoms later in the day.
“long-acting preparations may minimize the daily peaks and troughs of therapeutic effects associated with the shorter acting agents and also minimize the potential for rebound symptoms later in the day”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [9]
Following administration, conversion of LDX to d-amphetamine occurs in approximately 1.5 hours, with duration from 1.5 to 13 hours in children and 2 to 14 hours in adults.
“Following administration, conversion of LDX to d-amphetamine occurs in approximately 1.5 hours, with duration from 1.5 to 13 hours in children and 2 to 14 hours in adults.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [9]
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765 · see citing works
Molina, B. S. G., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c23d0 · Cited by 1,182 · see citing works
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · see citing works
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · see citing works
Do Stimulants Protect Against Psychiatric Disorders in Youth With ADHD? A 10-Year Follow-up Study
Biederman, J., Monuteaux, M. C., Spencer, T., Wilens, T. E., & Faraone, S. V. (2009) · Pediatrics · doi:10.1542/peds.2008-3347 · Cited by 246 · see citing works
Biederman, J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.10.1730 · Cited by 183 · see citing works
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · see citing works
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136 · see citing works
Self-citationthe 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 112 · see citing works
Stimulant Rebound: How Common Is It and What Does It Mean?
Carlson, G. A., & Kelly, K. L. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322163853 · Cited by 76 · see citing works
ADHD in Children, Adolescents, and Adults
Katragadda, S., & Schubiner, H. (2007) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2007.04.012 · Cited by 61 · see citing works
Silva, R. R., Muniz, R., Pestreich, L., Childress, A., Brams, M., Lopez, F. A., & Wang, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.239 · Cited by 44 · see citing works
Self-citationFaraone, S. V. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1565 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wu, E. Q., Hodgkins, P., Ben-Hamadi, R., Setyawan, J., Xie, J., Sikirica, V., Du, E. X., Yan, S. Y., & Erder, M. H. (2012) · CNS Drugs · doi:10.2165/11633900-000000000-00000 · Cited by 58 · see citing works
Childress, A. C., Arnold, V., Adeyi, B., Dirks, B., Babcock, T., Scheckner, B., Lasser, R., & Lopez, F. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712448252 · Cited by 33 · see citing works
Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
Wigal, T., Brams, M., Gasior, M., Gao, J., & Giblin, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2275 · Cited by 17 · see citing works
Self-citationReview of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Najib, J., Wimer, D., Zeng, J., Lam, K. W., Romanyak, N., Paige Morgan, E., & Thadavila, A. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517728090 · Cited by 17 · see citing works
- Authors
- Brams, M., Moon, E., Pucci, M., & López, F. A.
- Affiliations
- Baylor College of Medicine (US)
- Clinical Trials Ontario (CA)
- Corresponding author
- Brams, Matthew
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2010-05-24
- Volume
- 26
- Issue
- 8
- Pages
- 1809-1825
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2128109178
- Cited by
- 30
- References
- 13
- Citations by year
- 2025: 2 · 2024: 1 · 2020: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 6
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neuroethics, Human Enhancement, Biomedical Innovations
- Keywords
- attention deficit hyperactivity disorder, long-acting stimulants, methylphenidate, lisdexamfetamine dimesylate, children
- MeSH terms
- Lisdexamfetamine Dimesylate, Administration, Oral, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Clinical Trials as Topic, Dextroamphetamine, Drug Administration Schedule, Humans, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
